Advanced Liver Cancer Market Report 2026

The advanced liver cancer market size has grown rapidly in recent years. It will grow from $2.16 billion in 2025 to $2.49 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rising incidence of liver cancer, adoption of ct and mri imaging, growing demand for biopsy procedures, increasing cancer research funding, development of diagnostic centers and academic institutes.

The advanced liver cancer market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to advancement in genomic testing technologies, increasing implementation of personalized medicine, growth of screening and predictive diagnostics, rising collaborations between hospitals and research centers, expansion of ambulatory surgical centers. Major trends in the forecast period include rising adoption of ngs and genomic testing for hcc, increasing use of imaging and biopsy techniques, growth in prognostic and predictive diagnostics, expansion of liver cancer research initiatives, focus on early detection and personalized treatment approaches.

The rising prevalence of long-term hepatitis infections is expected to drive the growth of the advanced liver cancer market in the coming years. Long-term hepatitis infections are persistent viral infections lasting more than six months and can result in liver damage, cirrhosis, or liver cancer. The increase in these infections is linked to factors such as inadequate screening and vaccination, as well as delayed access to treatment. Chronic hepatitis B (HBV) or hepatitis C (HCV) infections are among the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most common form of liver cancer. Persistent viral infections can cause liver inflammation, progressive liver damage, and ultimately cancer over time. As these infections remain widespread, more individuals are at risk of developing advanced liver cancer. For instance, in April 2025, according to ASHM, an Australia-based peak organization of health professionals, approximately 219,800 individuals in Australia were living with chronic hepatitis B (CHB) in 2023, representing around 0.82% of the country’s population. Therefore, the rising prevalence of long-term hepatitis infections is contributing to the growth of the advanced liver cancer market.

Major companies in the advanced liver cancer market are focusing on establishing integrated multidisciplinary clinics to enhance patient-centered care, improve treatment coordination, and streamline clinical decision-making. A multidisciplinary clinic brings together specialists from oncology, hepatobiliary surgery, interventional radiology, genetics, pathology, anesthesia, and palliative care to collaboratively design treatment plans for complex liver cancer cases, ensuring personalized interventions and reduced delays. For instance, in July 2025, Apollo Proton Cancer Centre, an India-based cancer-treatment provider, launched its Advanced Liver Cancers Clinic, integrating care for primary liver cancers and liver metastases in a single center. The clinic brings together medical oncologists, hepatobiliary surgeons, interventional radiologists, geneticists, pathologists, and palliative care experts to establish standardized treatment pathways. It also plans to conduct prospective research, explore novel therapies, and prioritize the patient’s overall care journey, addressing the growing demand for specialized liver cancer programs in India amid a rising burden of hepatocellular carcinoma driven by hepatitis, fatty liver disease, and late diagnosis.

In March 2023, the University of Southern California (USC), a US-based private research university, partnered with Auransa Inc. to advance clinical trials for a new targeted liver cancer treatment. This collaboration leverages their combined expertise to improve treatment outcomes for liver cancer and other solid tumors. Auransa Inc. is a US-based pharmaceutical company focused on treating advanced liver cancers.

Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

North America was the largest region in the advanced liver cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced liver cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the advanced liver cancer market by increasing costs for imported diagnostic equipment, sequencing kits, and imaging devices. Segments such as genomic tests, imaging tests, and biopsy instruments are most affected, with regions including north america, europe, and asia-pacific research hubs facing higher procurement costs. These tariffs have led to increased operational expenses and longer supply chains. On the positive side, tariffs encourage local manufacturing, promote regional production capacities, and drive investment in cost-efficient diagnostic solutions.

The advanced liver cancer market research report is one of a series of new reports that provides advanced liver cancer market statistics, including advanced liver cancer industry global market size, regional shares, competitors with a advanced liver cancer market share, detailed advanced liver cancer market segments, market trends and opportunities, and any further data you may need to thrive in the advanced liver cancer industry. This advanced liver cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Advanced liver cancer, also known as hepatocellular carcinoma (HCC) in its later stages, refers to liver cancer that has either spread beyond the liver or grown large enough to significantly impair liver function. At this stage, the cancer may have invaded nearby blood vessels, lymph nodes, or distant organs, making treatment more complex. Common symptoms include jaundice, abdominal pain, weight loss, and fatigue.

The main test types for advanced liver cancer include imaging tests, biopsies, genomic tests, and others. Imaging tests play a key role in diagnosing, staging, and managing hepatocellular carcinoma (HCC) by providing detailed images of the liver and surrounding structures. These tests involve various technologies such as fluorescent in situ hybridization, next-generation sequencing, fluoroimmunoassay, comparative genomic hybridization, immunohistochemistry, and others. They are distributed through multiple channels, including direct tenders and retail sales. Advanced liver cancer testing is applicable for screening, diagnostic, predictive, prognostic, and research purposes, and is used by hospitals, cancer research centers, academic institutes, diagnostic centers, ambulatory surgical centers, and other end users.

The advanced liver cancer market consists of revenues earned by entities that provide services such as diagnostic services, surgical services, patient support and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced liver cancer market also includes sales of biopsy tools, computed tomography (CT) scans, liver function tests kit, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.